Login to Your Account

Amgen Confirms GDNF Halt In Parkinson's Development

By Jennifer Boggs

Monday, February 14, 2005
Amgen Inc. will return to the drawing board with its drug for Parkinson's disease, GDNF, after further review of preclinical studies showed a risk of brain damage. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription